Daniel L Kisner (18 results)
Language: English
Published by Springer, 1985
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Hardcover
Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contact seller5-star sellerCondition: Used - As new
£ 108.20
£ 1.99 shippingShips within U.S.A.Quantity: 15 available
Condition: As New. Unread book in perfect condition.
Language: English
Published by Springer, 2011
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Softcover
Seller: Ria Christie Collections, Uxbridge, United KingdomRia Christie Collections
Contact seller5-star sellerCondition: New
£ 95.42
£ 11.98 shippingShips from United Kingdom to U.S.A.Quantity: Over 20 available
Condition: New. In.
Language: English
Published by Springer, 1985
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Hardcover
Seller: Ria Christie Collections, Uxbridge, United KingdomRia Christie Collections
Contact seller5-star sellerCondition: New
£ 96.88
£ 11.98 shippingShips from United Kingdom to U.S.A.Quantity: Over 20 available
Condition: New. In.
Language: English
Published by Springer, 1985
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Hardcover
Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contact seller5-star sellerCondition: New
£ 112.58
£ 1.99 shippingShips within U.S.A.Quantity: 15 available
Condition: New.
Language: English
Published by Springer, 1985
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Hardcover
Seller: GreatBookPricesUK, Woodford Green, United KingdomGreatBookPricesUK
Contact seller5-star sellerCondition: New
£ 96.87
£ 15.00 shippingShips from United Kingdom to U.S.A.Quantity: Over 20 available
Condition: New.
Language: English
Published by Springer, 1985
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Hardcover
Seller: GreatBookPricesUK, Woodford Green, United KingdomGreatBookPricesUK
Contact seller5-star sellerCondition: Used - As new
£ 107.98
£ 15.00 shippingShips from United Kingdom to U.S.A.Quantity: Over 20 available
Condition: As New. Unread book in perfect condition.
Language: English
Published by Springer, 1985
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Hardcover
Seller: Books Puddle, New York, NY, U.S.A.Books Puddle
Contact seller4-star sellerCondition: New
£ 139.88
£ 3.01 shippingShips within U.S.A.Quantity: 4 available
Condition: New. pp. 128.
More imagesLanguage: English
Published by Springer, 2011
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Softcover
Seller: preigu, Osnabrück, Germanypreigu
Contact seller5-star sellerCondition: New
£ 84.93
£ 60.31 shippingShips from Germany to U.S.A.Quantity: 5 available
Taschenbuch. Condition: Neu. Interferon Alpha-2: Pre-Clinical and Clinical Evaluation | Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 | Daniel L. Kisner (u. a.) | Taschenbuch | xii | Englisch | 2011 | Springer | EAN 9781461296188… | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Language: English
Published by Springer US, 2011
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Softcover
Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH
Contact seller5-star sellerCondition: New
£ 100.08
£ 52.59 shippingShips from Germany to U.S.A.Quantity: 1 available
Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus cular an…d subcutaneous routes. Clinical toxicity principally involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.
Language: English
Published by Springer US, 1985
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Hardcover
Seller: moluna, Greven, Germanymoluna
Contact seller5-star sellerCondition: New
£ 113.46
£ 42.21 shippingShips from Germany to U.S.A.Quantity: Over 20 available
Condition: New. Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone .
Language: English
Published by Springer, 1985
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Hardcover
Seller: Mispah books, Redhill, SURRE, United KingdomMispah books
Contact seller4-star sellerCondition: Used - Very good
£ 155.00
£ 25.00 shippingShips from United Kingdom to U.S.A.Quantity: 1 available
Hardcover. Condition: Very Good. Very Good. book.
Language: English
Published by Springer Us Apr 1985, 1985
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Hardcover
Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH
Contact seller5-star sellerCondition: New
£ 138.69
£ 53.24 shippingShips from Germany to U.S.A.Quantity: 2 available
Buch. Condition: Neu. Neuware - Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus cular and subcutaneous routes. Clinical toxicity principal…ly involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.
Language: English
Published by Springer, 2011
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Softcover
- Print on Demand
Seller: Brook Bookstore On Demand, Napoli, NA, ItalyBrook Bookstore On Demand
Contact seller5-star sellerCondition: New
£ 76.54
£ 3.45 shippingShips from Italy to U.S.A.Quantity: Over 20 available
Condition: new. Questo è un articolo print on demand.
Language: English
Published by Springer US Okt 2011, 2011
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Softcover
- Print on Demand
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermanyBuchWeltWeit Ludwig Meier e.K.
Contact seller5-star sellerCondition: New
£ 104.41
£ 19.82 shippingShips from Germany to U.S.A.Quantity: 2 available
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, i…ntramus cular and subcutaneous routes. Clinical toxicity principally involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated. 128 pp. Englisch.
Language: English
Published by Springer US, 2011
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Softcover
- Print on Demand
Seller: moluna, Greven, Germanymoluna
Contact seller5-star sellerCondition: New
£ 81.89
£ 42.21 shippingShips from Germany to U.S.A.Quantity: Over 20 available
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 Interferon alpha-2 is a genetically engineered, highly purified pharma…ceutical agent that has undergone .
Language: English
Published by Springer, Springer Okt 2011, 2011
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Softcover
- Print on Demand
Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germanybuchversandmimpf2000
Contact seller5-star sellerCondition: New
£ 94.95
£ 51.70 shippingShips from Germany to U.S.A.Quantity: 1 available
Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intra…mus cular and subcutaneous routes. Clinical toxicity principally involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 128 pp. Englisch.
Language: English
Published by Springer, 1985
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Hardcover
- Print on Demand
Seller: Majestic Books, Hounslow, United KingdomMajestic Books
Contact seller4-star sellerCondition: New
£ 147.15
£ 6.50 shippingShips from United Kingdom to U.S.A.Quantity: 4 available
Condition: New. Print on Demand pp. 128 52:B&W 6.14 x 9.21in or 234 x 156mm (Royal 8vo) Case Laminate on White w/Gloss Lam.
Language: English
Published by Springer, 1985
Series: Developments in Oncology, Book 75 of 78. Book 75 of 78 - Developments in Oncology
- Hardcover
- Print on Demand
Seller: Biblios, frankfurt am main, HESSE, GermanyBiblios
Contact seller4-star sellerCondition: New
£ 150.91
£ 8.57 shippingShips from Germany to U.S.A.Quantity: 4 available
Condition: New. PRINT ON DEMAND pp. 128.
